• Explore /
  • Poster
  • / Integrate II: A randomised phase 3 double-blind placebo-controlled study of regorafenib in refractory advanced gastro-oesophageal cancer (AGOC)—An international study organized by the Australasian Gastrointestinal Trials Group (AGITG).

Integrate II: A randomised phase 3 double-blind placebo-controlled study of regorafenib in refractory advanced gastro-oesophageal cancer (AGOC)—An international study organized by the Australasian Gastrointestinal Trials Group (AGITG).

Abstract Poster

Authors

Katrin Sjoquist

Katrin Marie Sjoquist

NHMRC Clinical Trials Centre, The University of Sydney, Sydney, Australia

Katrin Marie Sjoquist , Nick Pavlakis , Andrew James Martin , Eric Tsobanis , Sonia Yip , Yung-Jue Bang , Thierry Alcindor , Christopher J. O'Callaghan , Kohei Shitara , Tanios S. Bekaii-Saab , Axel Grothey , Li-Tzong Chen , John Simes , John Raymond Zalcberg , David Goldstein

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2017 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gastrointestinal (Noncolorectal) Cancer

Track

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Sub Track

Esophageal or Gastric Cancer

Clinical Trial Registration Number

NCT02773524

Citation

J Clin Oncol 35, 2017 (suppl; abstr TPS4136)

DOI

10.1200/JCO.2017.35.15_suppl.TPS4136

Abstract #

TPS4136

Poster Bd #

125b

Abstract Disclosures

Similar Posters

First Author: Nick Pavlakis

First Author: Nick Pavlakis

First Author: Nick Pavlakis

First Author: Anuj Kishor Patel